Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

oncoprescribe-top

Advertisement

TAVALISSE® (Fostamatinib disodium hexahydrate)

April 27, 2018April 5, 2020 RR FDA Approvals
Immune Thrombocytopenic Purpura

The FDA on April 17, 2018 approved TAVALISSE® for the treatment of thrombocytopenia in adult patients with chronic Immune Thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE® is a product of Rigel Pharmaceuticals, Inc.

Related Posts:

  • FDA Approves TAVALISSE® for Chronic ITP

Post navigation

OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab)
TAGRISSO® (Osimertinib)

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

oncoprescribe-ad

Advertisement

Ad 2

OncoPrescribe

Advertisement

Ad 3

OncoPrescribe.com-Ad

Advertisement

Ad 4

Immunization Schedule

Advertisement

  • HELP
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved